Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Hackensack Meridian Health
St. Jude Children's Research Hospital
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
City of Hope Medical Center
University of Illinois at Chicago
Dana-Farber Cancer Institute
Stanford University
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Children's Hospital Medical Center, Cincinnati
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Weill Medical College of Cornell University
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
University of Illinois at Chicago
City of Hope Medical Center
Fred Hutchinson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Northwestern University
Fred Hutchinson Cancer Center
Stanford University
University of Pittsburgh
City of Hope Medical Center
Columbia University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Northside Hospital, Inc.